CURIGIN
CURIGIN
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Address:
Songdong, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.curigin.co.kr
Status:
Active
Contact:
02-969-9055
Email Addresses:
[email protected]
Technology used in webpage:
SPF Domain Not Resolving Google Apps For Business Naver Cloud Platform
Current Employees Featured
Official Site Inspections
http://www.curigin.co.kr
- Host name: 49.50.163.51
- IP address: 49.50.163.51
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Curigin"
큐리진 - curigin.com
Curigin is a company focused on the development of new drugs with a sincere passion for research and development. After developing an adenoviral vector capable of delivering bispecific RNAi in 2018, more than 5 types of vectors …See details»
Curigin Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Curigin Co., Ltd. specializes in providing technology solutions for specific genes and diseases. This organization was established on February 1st, 2016 and is based in Seoul, …See details»
Curigin - Crunchbase Company Profile & Funding
Organization. Curigin . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Curigin is a medicine and pharmaceutical …See details»
Curigin Co., Ltd. - Golden
Organization. Company attributes. Industry. ... Curigin Co. Ltd. is a company that combines anti-cancer virus therapy and gene therapy. Its goal is to commercialize the bispecific shRNA …See details»
Curigin Company Profile 2024: Valuation, Funding & Investors
Curigin General Information Description. Developer of a gene therapy intended to treat diseases such as cancer. The company has developed a novel viral oncolytic gene therapy to target …See details»
Curigin Inc. - LinkedIn
Non-profit Organization Management Fairfield, NJ mCureX Therapeutics, Inc. ... Biotechnology venture developing innovative oncolytic RNAi therapies. | At Curigin, we are developing …See details»
Charles River Signs Two Gene Therapy Manufacturing …
Jun 12, 2023 Curigin’s lead candidate is CA102, a genetically engineered adenovirus for bladder cancer which, according to the World Cancer Research Fund, is the 10 th most common type of cancer worldwide ...See details»
Curigin - Funding, Financials, Valuation & Investors - Crunchbase
Jan 1, 2018 Curigin is a medicine and pharmaceutical research and development company. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …See details»
Curigin - Products, Competitors, Financials, Employees, …
About Curigin. Curigin focuses on the development of RNA-based therapeutics in the biotechnology sector. The company's main offerings include innovative therapies that utilize bi …See details»
Curigin - Overview, News & Competitors | ZoomInfo.com
At Curigin, we are developing innovative therapies using our novel bi-specific shRNA technology to simultaneously knockdown two different disease causing pathways. Our lead pipelines …See details»
Charles River and Curigin Collaborate to Produce Oncolytic RNAi …
Curigin’s lead candidate is CA102, a genetically engineered adenovirus for bladder cancer which, according to the World Cancer Research Fund, is the 10 th most common type of cancer …See details»
News from CRL, NorthX, and Avirmax - BioProcess Insider
Jun 14, 2023 First up in our contract development and manufacturing organization (CDMO) roundup is Charles River Laboratories (CRL). The firm has signed a deal with Korean …See details»
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
Jun 13, 2023 Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions. ... INADcure is a non-profit organization to support the …See details»
CA102 - Drug Targets, Indications, Patents - Synapse
About Curigin Curigin develops innovative therapies using novel bi-specific shRNA technology to simultaneously knockdown two different disease-causing pathways. Our lead pipelines target …See details»
Charles River and Curigin Collaborate to Produce Oncolytic RNAi …
Jun 12, 2023 The gene therapy developer will leverage Charles River's market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its …See details»
Charles River Laboratories, Curigin partner on gene therapy
Curigin president Jae-Gyun Jeong said: “Developing innovative therapeutics is our mission and we are steadily working towards that goal. “We are excited to work with Charles River in the …See details»
Investing in innovative approaches to oncology - Nature
Curigin’s lead pipeline asset, CA102, is a uniquely designed bispecific RNAi therapeutic delivered in a modified oncolytic adenovirus that suppresses two pivotal oncogenes: mammalian target …See details»
Charles River, Curigin partner for oncolytic RNAi gene therapy ...
Jun 13, 2023 Under the partnership, Curigin will use Charles River’s expertise in contract development and manufacturing organisation (CDMO) solutions for supporting its preclinical …See details»
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
Jun 13, 2023 Curigin’s lead candidate is CA102, a genetically engineered adenovirus for bladder cancer. Curigin currently expects to submit an Investigational New Drug application for CA102 …See details»
Csi 107 - AdisInsight - Springer
Sep 3, 2024 Csi 107 was a siRNA based therapeutic being developed by Curigin for the treatment of pulmonary fibrosis and cystic fibrosis. Curigin had established a Csi 107 Next ... If …See details»